February 15, 2016
Asahi Kasei Pharma Corp.
Pfizer Japan Inc.

Asahi Kasei Pharma Corp. (Head office: Chiyoda-ku, Tokyo, Japan; President: Kazuyoshi Hori; hereinafter 'Asahi Kasei Pharma') and Pfizer Japan Inc. (Shibuya-ku, Tokyo, Japan; President: Ichiro Umeda; hereinafter 'Pfizer') have reached a decision to end their co-promotion agreement in Japan for Recomodulin™ anticoagulant intravenous infusion 12800 (recombinant thrombomodulin alpha) which is manufactured and sold by Asahi Kasei Pharma, on March 31, 2016.

Asahi Kasei Pharma and Pfizer began co-promotion of Recomodulin™ in Japan on November 1, 2013. With the termination of the co-promotion agreement, promotion activities will be performed by Asahi Kasei Pharma alone from April 1, 2016, onward.

Press Releases

Asahi Kasei Corporation issued this content on 15 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 15 February 2016 06:22:17 UTC

Original Document: http://www.asahi-kasei.co.jp/asahi/en/news/2015/e160215_2.html